你好,请登录   免费注册    |    收藏本站
联系电话: 0574-87917803
联系电话: call_new 0574-87917803
HCC1428 BL
HCC1428 BL
规格:
货期:
编号:TS212049
品牌:Testobio
产品名称: HCC1428 BL
商品货号: TS212049
Organism: Homo sapiens, human
Tissue: peripheral blood
Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transforme
Product Format: frozen
Morphology: lymphoblast
Culture Properties: suspension, multicell aggregates
Biosafety Level: 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease: Carcinoma,Cancer,Cancer,Adenocarcinoma
Gender: female
Ethnicity: Caucasian, White
Applications:
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene.
Storage Conditions: liquid nitrogen vapor phase
Derivation:
HCC1428 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428.
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers.
Clinical Data:
HCC1428 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428.
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene.
female
Caucasian, White
Comments:
HCC1428 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428.
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers.
The homozygous deletion in the FHIT gene is retained in the lymphoblastoid line.
There is a familial history of breast cancer (maternal grandmother).
HCC1428, a metastatic breast adenocarcinoma cell line, is available as ATCC CRL-2327.
Complete Growth Medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 5 x 105 viable cells/mL. Maintain cultures at cell concentrations between 5 x 105 and 1.5 x 106 viable cells/mL.
Medium Renewal:xa0Every 2 to 3 days
Cryopreservation:

Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X.

Culture Conditions:
Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5%
Name of Depositor: AF Gazdar, AK Virmani
References:

Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771

Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC.

Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988.

Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC.

首页 > 产品中心 > 微生物培养 > 菌株 > null > HCC1428 BL

HCC1428 BL

  • 货号: TS212049
  • 好评
询价
  • 品牌 : TESTOBIO
产品名称: HCC1428 BL
商品货号: TS212049
Organism: Homo sapiens, human
Tissue: peripheral blood
Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transforme
Product Format: frozen
Morphology: lymphoblast
Culture Properties: suspension, multicell aggregates
Biosafety Level: 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease: Carcinoma,Cancer,Cancer,Adenocarcinoma
Gender: female
Ethnicity: Caucasian, White
Applications:
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene.
Storage Conditions: liquid nitrogen vapor phase
Derivation:
HCC1428 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428.
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers.
Clinical Data:
HCC1428 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428.
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene.
female
Caucasian, White
Comments:
HCC1428 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428.
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers.
The homozygous deletion in the FHIT gene is retained in the lymphoblastoid line.
There is a familial history of breast cancer (maternal grandmother).
HCC1428, a metastatic breast adenocarcinoma cell line, is available as ATCC CRL-2327.
Complete Growth Medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 5 x 105 viable cells/mL. Maintain cultures at cell concentrations between 5 x 105 and 1.5 x 106 viable cells/mL.
Medium Renewal:xa0Every 2 to 3 days
Cryopreservation:

Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X.

Culture Conditions:
Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5%
Name of Depositor: AF Gazdar, AK Virmani
References:

Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771

Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC.

Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988.

Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC.

合作单位: